Effects of Empagliflozin on Left Ventricular Diastolic Function Compared to Usual Care in Type 2 Diabetics

Summary

The purpose of the EmDia trial is to compare the effects of empagliflozin with placebo in addition to standard diabetic treatment or dietetic treatment on cardiac diastolic function in patients with type 2 Diabetes mellitus.

Timeline

Start

2016-10-10

Primary completion

2020-06-15

Completion

2020-08-31

Publications

• Schmitt F, Ten Cate V, Fischer Z, Hagen M, Steigenberger BA, Tenzer S, Wild PS, Schmidlin T. Metabolic Profiling of the EmDia Cohort by LC-MS Reveals Empagliflozin-Intake Associated Regulation of 1,5-anhydroglucitol and Urate. Proteomics. 2026 Jan;26(1):44-56. doi: 10.1002/pmic.70075. Epub 2025 Dec 3.
• Bauer KI, Baker D, Lerner R, Koeck T, Buch G, Fischer Z, Martens R, Esenkova EE, Nuber M, Andrade-Navarro MA, Ten Cate V, Tenzer S, Wild PS, Bindila L, Araldi E. Effect of Empagliflozin on the plasma lipidome in patients with type 2 diabetes mellitus: results from the EmDia clinical trial. Cardiovasc Diabetol. 2025 Sep 8;24(1):359. doi: 10.1186/s12933-025-02916-0.
• Prochaska JH, Junger C, Schulz A, Arnold N, Muller F, Heidorn MW, Baumkotter R, Zahn D, Koeck T, Trobs SO, Lackner KJ, Daiber A, Binder H, Shah SJ, Gori T, Munzel T, Wild PS. Effects of empagliflozin on left ventricular diastolic function in addition to usual care in individuals with type 2 diabetes mellitus-results from the randomized, double-blind, placebo-controlled EmDia trial. Clin Res Cardiol. 2023 Jul;112(7):911-922. doi: 10.1007/s00392-023-02164-w. Epub 2023 Feb 10.
• Junger C, Prochaska JH, Gori T, Schulz A, Binder H, Daiber A, Koeck T, Rapp S, Lackner KJ, Munzel T, Wild PS. Rationale and design of the effects of EMpagliflozin on left ventricular DIAstolic function in diabetes (EmDia) study. J Cardiovasc Med (Hagerstown). 2022 Mar 1;23(3):191-197. doi: 10.2459/JCM.0000000000001267.

Drugs

Indications